Not yet recruitingInterventionalPhase 2Last updated Aug 10, 2026

A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

Overview

ClinicalTrials.gov ID: NCT07756346
Lead Sponsor: University of Massachusetts, WorcesterOTHER
Brief Summary: This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease hidradenitis suppurativa (HS). In this study, the investigators will extend data from a 12-week pilot study to rigorously test the hypothesis that botulinum toxin (BoNT) therapy reduces disease severity and relieves HS pain symptoms..
Study Type

Status

Study Record Dates

NCT05403710Recruiting

Botulinum Toxin Therapy in Hidradenitis Suppurativa

NCT06237465Withdrawn

Botulinum Toxin-A for Hidradenitis Suppurativa

NCT03103074Completed

Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa

NCT06603077Completed

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT05103423Completed

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05620836Completed

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)